BACKGROUND Vascular endothelial growth factor (VEGF)-B activates cytoprotective/antiapoptotic and minimally
VEGF-B, 1 of the 5 members of the mammalian VEGF family, is a major pro-survival (rather than pro-angiogenic) factor (8) . It selectively binds vascular endothelial growth factor receptor (VEGFR)-1, whereas the more extensively studied pro-angiogenic VEGF-A binds both VEGFR-1 and vascular endothelial growth factor receptor-2 (VEGFR-2). The marked cytoprotective/antiapoptotic (9) and minimally angiogenic action of VEGF-B renders it particularly well suited for gene therapy of nonischemic dilated cardiomyopathy (DCM), a severe pathological condition not caused by coronary artery disease in which the increased rate of apoptosis seems to play a major role (10) (11) (12) . Unfortunately, no specific antiapoptotic pharmacological agents are currently available to clinicians.
Although DCM occurs much less frequently than ischemic disease, it remains largely untreatable and is responsible for most U.S. cardiac transplants (13) .
VEGF-B-based cytoprotective therapy might prove successful in the fight against this severe pathological condition. Therefore, the goal of the present study was to: 1) validate a clinically applicable cardioselective VEGF-B gene therapy in a large animal model of DCM; 2) test the efficacy of a safer approach on the basis of inducible VEGF-B transgenes turned on and off in response to, respectively, the occurrence or remission of the pathological condition; and 3) test the hypothesis that VEGFR-1 is the principal mediator of the cytoprotective action exerted by VEGFs. We delivered VEGF-B 167 , the prevalent VEGF-B isoform (14) , in canine tachypacing-induced HF. This is the best-characterized model of DCM, reproducing numerous pathophysiological and molecular alterations of the human disease (7, (15) (16) (17) . Parallel experiments were conducted in cultured cardiomyocytes.
METHODS
Fifty-three adult male, mongrel dogs (22 to 25 kg body weight) were chronically instrumented as previously described (Online Appendix) (7, 17, 18) . The dogs To induce HF, dogs were subjected to left ventricular (LV) pacing with an external pacemaker set at 210 beats/min for 3 weeks; the pacing rate was increased to 240 beats/min for an additional week. On the basis of our previous studies (17, 18) , this pacing protocol causes DCM and compensated HF during the first 3 weeks, culminating in severe HF at 27 to 30 days. All of the dogs were killed at 28 days to compare in vivo and ex vivo data at a fixed time point.
The protocol was approved by the Institutional Animal Care and Use Committee of Temple University, and it conformed to the guiding principles for the care and use of laboratory animals published by the National Institutes of Health.
Histological and polymerase chain reaction analysis of cardiac tissue was performed as previously described by us (Online Appendix) (6, 7, 19, 20) .
To determine cytoprotective effects of VEGF-B 167 , neonatal rat cardiomyocytes were isolated and cultured with production of reactive oxygen species measured as previously described (19, 21, 22) . They were exposed to VEGF-B 167 , VEGF-A, VEGF-E, and placental growth factor in the absence or in the presence of angiotensin II or norepinephrine (50 M -6 ). Woitek et al.
28 days of pacing, the functional parameters were monitored, and the animals were killed 2 weeks later. As expected, these dogs' hemodynamic values returned to normal or quasi-normal values ( Figure 4A ). Gene transfer therapy appears effective in halting heart failure (HF) progression as seen in comparisons between main hemodynamic changes, over 4 weeks of chronic cardiac pacing, in dogs with intracoronary infusion of AAV-CMV-GFP (control, n ¼ 10) or AAV-CMV-VEGF-B. This latter was administered at the beginning of the pacing protocol (n ¼ 10) or after 14 days of pacing (delayed AAV-CMV-VEGF-B, n ¼ 8).
*p < 0.05 versus day 0 (baseline) within group; †p < 0.05 versus day 14 within group; #p < 0.05 versus AAV-CMV-GFP at the same time point.
LV ¼ left ventricular; other abbreviations as in Figures 1 and 2 .
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VEGF-B 167 Gene Therapy in DCM Woitek et al. LV tachypacing causes dyssynchronous contraction, leading to an asymmetric contractile impairment, more pronounced in the LV free wall compared with the septum (30) . In our experiments, AAV was delivered intracoronarily, without targeting specific regions of the heart. Therefore, we assessed whether gene therapy was similarly beneficial in the LV free whereas VEGF-B does not change significantly (7, 16) .
Although intracoronary AAV infusion has been previously used in several large animal and human studies, to our knowledge, no detailed description of myocardial transduction efficiency and regional heterogeneities was provided. We chose the serotype 9
AAV for its known cardiotropism (3, 35) . However, by using the GFP reporter, we found that the trans- 
